Blue test tubes arranged in a line, disappearing into the background

Drug news

EU approves Xofigo (Bayer) for Prostate Cancer

Read time: 1 mins

Last updated:17th Nov 2013

Published:17th Nov 2013

Source: Pharmawand

Bayer HealthCare announced that the European Commission (EC) on 15 November 2013 has granted marketing authorisation for Xofigo 1000 kBq/ml, solution for injection (radium Ra 223 dichloride) for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases. The approval of Xofigo is based on data from the pivotal Phase III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) trial.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

Abbott initiates clinical study to evaluate the use of its deep brain stimulation system to manage severe depression.

Abbott announced it has initiated a pivotal clinical trial, called the TRANSCEND study, to evaluate the use of the company's deep brain stimulation (DBS) system to manage treatment-resistant depression (TRD), a form of major depressive disorder.

2 mins

Drug news

Positive results from phase III trial of Nucala (mepolizumab) announced in COPD.-GSK

GSK plc announced positive headline results of MATINEE, the phase III clinical trial evaluating Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5) in adults with chronic obstructive pulmonary disease (COPD).

1 min

Drug news

Roche presents new 48-week data for the Bruton’s tyrosine kinase (BTK) inhibitor fenebrutinib from the phase II FENopta open-label extension (OLE) study at the ECTRIMS conference.

Roche presents new 48-week data for the investigational Bruton’s tyrosine kinase (BTK) inhibitor fenebrutinib from the Phase II FENopta open-label extension (OLE) study at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Copenhagen, Denmark on 18 September 2024.

2 min

See all news